Roy M. Matining

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

Babafemi Taiwo, Lu Zheng, Sébastien Gallien et al. · AIDS · 2011 · 147 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial

Susan E. Krown, Carlee Moser, Patrick MacPhail et al. · The Lancet · 2020 · 91 citations · Full text

Medicine, Infectious Diseases, Oncology +6

Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk

Pablo Tebas, William Henry, Roy M. Matining et al. · PLoS ONE · 2008 · 61 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13

Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study

Mark Sulkowski, Minhee Kang, Roy M. Matining et al. · The Journal of Infectious Diseases · 2013 · 55 citations

Pharmacy, Infectious Diseases, Pharmacology +14

Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving Combination Antiretroviral Therapy

Benigno Rodríguez, David M. Asmuth, Roy M. Matining et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2013 · 53 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17